Gene · 9020
MAP3K14: mitogen-activated protein kinase kinase kinase 14
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. MAP3K14: mitogen-activated protein kinase kinase kinase 14. Genes, record 9020. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9020
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99558 | Mitogen-activated protein kinase kinase kinase 14 | 947 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents24
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 18343 | Q99558 | Espacenet |
| JP 2025524002 A | 2025-07-25 | 19 | Q99558 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 18343 | Q99558 | Espacenet |
| KR 1020250039465 A | 2025-03-20 | 19 | Q99558 | Espacenet |
| JP 2024023699 A | 2024-02-21 | 19 | Q99558 | Espacenet |
| JP 2024505890 A | 2024-02-08 | 19 | Q99558 | Espacenet |
| JP 2023509886 A | 2023-03-10 | 19 | Q99558 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 52541 | Q99558 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 52543 | Q99558 | Espacenet |
| KR 1020220123023 A | 2022-09-05 | 19 | Q99558 | Espacenet |
1 to 10 of 24
See all 24 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,408
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MAP3K14 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 40 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA072720 | Cancer Center Support Grant | 10 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 9 | 2025 |
| P30ES005605 | Environmental Health Sciences Research Center | 8 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 7 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 7 | 2025 |
| P01CA100730 | Retrovirus Models of Cancer | 6 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 6 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 6 | 2025 |
1 to 10 of 2,408Source NIH's project files
See all 2,408 nih grantsPapers3,446
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Glucose-deprived tumor microenvironment activates AMP-activated protein kinase to drive adoptively transferred T helper 9 cell senescence. | Immunity | 2026 | 42822442 | PubTator, text mining | PubMed |
| UBE2L6 drives ulcerative colitis progression by promoting BIRC2 degradation and activating non-canonical NF-κB signalling. | Inflamm Res | 2026 | 42786362 | PubTator, text mining | PubMed |
| From M1/M2 polarization to disease-associated microglial states: refining the role of NIK in diabetic retinopathy. | J Transl Med | 2026 | 42750059 | PubTator, text mining | PubMed |
| KSHV promotes leukocyte adhesion and transendothelial migration via induction of VCAM1. | mBio | 2026 | 42708602 | PubTator, text mining | PubMed |
| MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies. | Blood | 2026 | 42683823 | PubTator, text mining | PubMed |
| ELF3 links kidney function GWAS loci to maladaptive epithelial inflammation. | Sci Adv | 2026 | 42497247 | PubTator, text mining | PubMed |
| Targeting tumor cell-intrinsic POU4F1 enhances antitumor immunity and sensitizes tumors to immunotherapy in basal-like breast cancer by modulating macrophage recruitment and polarization. | Cancer Lett | 2026 | 42492831 | PubTator, text mining | PubMed |
| A Detrimental NFKB2 Missense Variant is Associated with Hypogammaglobulinemia. | J Clin Immunol | 2026 | 42432294 | PubTator, text mining | PubMed |
| Could we discuss the molecular signature of immune dysregulation? | Clin Exp Immunol | 2026 | 42400499 | PubTator, text mining | PubMed |
| Overexpression of SLC44A4 suppresses ferroptosis and reduces lipid peroxidation via noncanonical NF-κB signaling in a NIK-dependent manner. | Ann Med | 2026 | 42186342 | PubTator, text mining | PubMed |
1 to 10 of 3,446
See all 3,446 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9020
GET https://conductscience.org/api/genes/v1/9020/patents?page=2